Laquinimod (ABR-215062) for the treatment of relapsing multiple sclerosis

Expert Review of Clinical Pharmacology

Volumn 9, Issue 1, 2016, Pages 49-57

  Constantinescu, Simona E ^a   Constantinescu, Cris S ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

cytokines; demyelination; immunomodulation; innate immune system; laquinimod; multiple sclerosis; neuroprotection; Nf kB

Indexed keywords

LAQUINIMOD; PLACEBO; IMMUNOLOGIC FACTOR; QUINOLONE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; BUDD CHIARI SYNDROME; DEPRESSION; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL DISEASE; HUMAN; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; MUSCLE TIGHTNESS; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; ANIMAL; BRAIN; DISEASE MODEL; DRUG EFFECTS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PATHOLOGY; PATHOPHYSIOLOGY;

ADMINISTRATION, ORAL; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; IMMUNOLOGIC FACTORS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; QUINOLONES;

EID: 84949103432     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2016.1108189     Document Type: Review

References (37)

1. Polman CH, Uitdehaag BM. Drug treatment of multiple sclerosis. BMJ. 2000; 321 (7259): 490-494
2. Haggiag S, Ruggieri S, Gasperini C. Efficacy and safety of laquinimod in multiple sclerosis: current status. Ther Adv Neurol Disord. 2013; 6 (6): 343-352
3. Patwardhan MB, Matchar DB, Samsa GP., et al. Cost of multiple sclerosis by level of disability: a review of literature. Mult Scler. 2005; 11 (2): 232-239
4. Lucchinetti CF, Bruck W, Rodriguez M., et al. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol. 1996; 6 (3): 259-274
5. Ontaneda D, Fox RJ, Chataway J. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol. 2015; 14 (2): 208-223
6. Lugaresi A, di Ioia M, Travaglini D., et al. Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. Neuropsychiatr Dis Treat. 2013; 9: 893-914
7. Tanasescu R, Ionete C, Chou IJ., et al. Advances in the treatment of relapsing-remitting multiple sclerosis. Biomed J. 2014; 37 (2): 41-49
8. Wolinsky JS, Narayana PA, Noseworthy JH., et al. Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators. Neurology. 2000; 54 (9): 1734-1741
9. Tan IL, Lycklama a Nijeholt GJ, Polman CH., et al. Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials. Mult Scler. 2000; 6 (2): 99-104
10. Yang J-S, Xu L-Y, Xiao B-G., et al. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-β in Lewis rats. J Neuroimmunol. 2004; 156 (1-2): 3-9
11. Brück W, Wegner C. Insight into the mechanism of laquinimod action. J Neurol Sci. 2011; 306 (1-2): 173-179
12. Fernandez O. Oral laquinimod treatment in multiple sclerosis. Neurologia. 2011; 26 (2): 111-117
13. Constantinescu CS, Farooqi N, O'Brien K., et al. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol. 2011; 164 (4): 1079-1106
14. Wegner C, Stadelmann C, Pfortner R., et al. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol. 2010; 227 (1-2): 133-143
15. Ruffini F, Rossi S, Bergamaschi A., et al. Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis. Mult Scler. 2013; 19 (8): 1084-1094
16. Schulze-Topphoff U, Shetty A, Varrin-Doyer M., et al. Laquinimod, a quinoline-3-carboxamide, induces type ii myeloid cells that modulate central nervous system autoimmunity. PLoS ONE. 2012; 7 (3): e33797
17. Mishra MK, Wang J, Silva C., et al. Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod. Am J Pathol. 2012; 181 (2): 642-651
18. Toubi E, Nussbaum S, Staun-Ram E., et al. Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis. J Neuroimmunol. 2012; 251 (1-2): 45-54
19. Zilkha-Falb R, Gurevich M, Hayardeny L., et al. The role of laquinimod in modulation of the immune response in relapsing-remitting multiple sclerosis: lessons from gene expression signatures. J Neuroimmunol. 2015; 283: 11-16
20. Jolivel V, Luessi F, Masri J., et al. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis. Brain 2013;136: 1048-1066
21. Blakemore WF. Observations on oligodendrocyte degeneration, the resolution of status spongiosus and remyelination in cuprizone intoxication in mice. J Neurocytol. 1972; 1 (4): 413-426
22. Bruck W, Pfortner R, Pham T., et al. Reduced astrocytic NF-kappaB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 2012; 124 (3): 411-424
23. Raasch J, Zeller N, van Loo G., et al. IkappaB kinase 2 determines oligodendrocyte loss by non-cell-Autonomous activation of NF-kappaB in the central nervous system. Brain. 2011; 134 (Pt 4): 1184-1198
24. Wujek JR, Bjartmar C, Richer E., et al. Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. J Neuropathol Exp Neurol. 2002; 61 (1): 23-32
25. Centonze D, Muzio L, Rossi S., et al. Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J Neurosci. 2009; 29 (11): 3442-3452
26. Rossi S, Muzio L, De Chiara V., et al. Impaired striatal GABA transmission in experimental autoimmune encephalomyelitis. Brain Behav Immun. 2011; 25 (5): 947-956
27. Thöne J, Ellrichmann G, Seubert S., et al. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am J Pathol. 2012; 180 (1): 267-274
28. Thone J, Gold R. Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis. Expert Opin Drug Metab Toxicol. 2011; 7 (3): 365-370
29. Polman C, Barkhof F, Sandberg-Wollheim M., et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology. 2005; 64 (6): 987-991
30. Comi G, Pulizzi A, Rovaris M., et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008; 371 (9630): 2085-2092
31. Filippi M, Rovaris M, Capra R., et al. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials. Brain. 1998; 121 (Pt 10): 2011-2020
32. Comi G, Abramsky O, Arbizu T., et al. Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. Mult Scler. 2010; 16 (11): 1360-1366
33. Comi G, Jeffery D, Kappos L., et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012; 366 (11): 1000-1009
34. Vollmer TL, Sorensen PS, Selmaj K., et al. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol. 2014; 261 (4): 773-783
35. clinicaltrials.gov. The efficacy and safety and tolerability of laquinimod in subjects with relapsing remitting multiple sclerosis (RRMS) (CONCERTO) [ cited 2015 Jul 28 ]. Available from: https://clinicaltrials.gov/ct2/show/NCT01707992
36. Barkhof F, Giovannoni G, Hartung HP., et al. ARPEGGIO: a randomized, placebo-controlled study to evaluate oral laquinimod in patients with primary progressive multiple sclerosis (PPMS). American Academy of Neurology; 2015 Apr 6. Washington (DC): Washington Convention Centre; 2015. p. Supplement P7.210
37. clinicaltrials.gov. A phase 2 clinical study in subjects with primary progressive multiple sclerosis to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/Day or 1.5mg/Day (experimental drug) as compared to placebo [ cited 2015 Jul 27 ]. Available from: https://clinicaltrials.gov/ct2/show/NCT02284568